PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthresbiomed central web sitesearch.manuscript submission.see also journal with issn 1478-6354registration.reference to the article.journal front page.
 
Arthritis Res. 2001; 3(Suppl A): P016.
Published online Jan 26, 2001. doi:  10.1186/ar185
PMCID: PMC3273212
Elevated IL-16 level is a non-genetic characteristic of patients with severe systemic lupus erythematosus
LR Lard,1 BO Roep,2 and TWJ Huizinga1
1Departments of Rheumatology and Immunohaematology
2Bloodbank, Leiden University Medical Center, Leiden, The Netherlands
Supplement
21st European Workshop for Rheumatology Research
Conference
21st European Workshop for Rheumatology Research
1-4 March 2001
Vienna, Austria
Received January 15, 2001
Introduction
IL-16, origanilly named lymphocyte chemoattractant factor, is a cytokine which is mainly produced by CD8+ T cells. Several reports have described that increased levels of IL-16 are in part responsible for T cell abnormalities in SLE patients. It is unknown if the previously reported increased levels of IL-16 is a characteristic underlying susceptibility to SLE or is a characteristic of the disease itself.
Methods
Accumulated organ damage was measured with the SLICC/ACR Damage Index. Twenty-five severe (SLICC/ACR: 4.9 ± 2.5) and ten non-severe (SLICC/ACR: 1.0 ± 0.8) SLE patients were included in this study. Also 11 first degree relatives and 12 healthy volunteers were included in this study. Plasma IL-16 levels were measured by ELISA.
Results
No significant difference in the IL-16 levels of the first degree relatives of patients with SLE (38.3 ± 11.1 pg/ml) were observed when compared to controls (31.2 ± 10.1 pg/ml). In order to analyze characteristics of the SLE in relation to concentration of IL-16, IL-16 was measured in severe SLE patients (71.3 ± 87.4 pg/ml; P = 0.025) compared to healthy controls. On the other hand, no significant differences were observed between the non-severe SLE patients (37.8 ± 26.1 pg/ml) and controls.
Conclusion
No evidence for increased IL-16 levels in first degree relatives of the SLE patients was observed. IL-16 is enhanced in SLE patients with a severe disease, but not in patients with non-severe disease, thereby suggesting that IL-16 is associated with disease severity, and not with susceptibility for SLE.
Articles from Arthritis Research are provided here courtesy of
BioMed Central